Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023Business Wire • 10/16/23
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023Business Wire • 10/12/23
If You Purchased Brand or Generic Truvada or Atripla Directly From the Manufacturer, You May Receive a Payment From a Class Action Settlement; Gilead Agreed to Pay $246,750,000 Into a Settlement Fund, Announces Roberts Law Firm, PC and NastLaw LLCBusiness Wire • 10/09/23
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023Business Wire • 10/03/23
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic ImpairmentBusiness Wire • 09/19/23
Kite's Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell LymphomaBusiness Wire • 09/18/23
Gilead Sciences, Inc. (GILD) Management Presents at Morgan Stanley 21st Annual Global Healthcare Brokers Conference 2023 (Transcript)Seeking Alpha • 09/12/23
Big Institutions Grab ‘Strong Buy' Dividend Stocks in a Sector Not Totally Driven by AI24/7 Wall Street • 09/11/23
Gilead's Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung CancerBusiness Wire • 09/10/23
The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A MonthInvestors Business Daily • 09/08/23